Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes
Publication Date
2014
Journal Title
J Clin Immunol
Abstract
An emerging paradigm for the treatment of primary immunodeficiency disease (PIDD) with immunoglobulin (IgG) replacement therapy emphasizes the tailoring of treatments to each patient with the goal of preventing infections and minimizing side effects. Increasing evidence shows that the IgG dose needed to prevent infection varies with each patient, and both intravenous immunoglobulin (IGIV) and subcutaneous immunoglobulin (IGSC) have emerged as feasible modes of delivery. Although IGIV is currently the routine treatment, IGSC is increasingly being chosen as the preferred route of delivery due to greater flexibility and reduced side effects.
Volume Number
37
Issue Number
2
Pages
190-196
Document Type
Article
EPub Date
2014/01/31
Status
Faculty
Facility
School of Medicine
Primary Department
General Pediatrics
Additional Departments
Molecular Medicine
PMID
DOI
10.1007/s10875-014-9990-x